AIM ImmunoTech Net Income vs. Operating Margin

AIM Stock  USD 0.72  0.02  2.86%   
Considering the key profitability indicators obtained from AIM ImmunoTech's historical financial statements, AIM ImmunoTech's profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess AIM ImmunoTech's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1995-01-31
Previous Quarter
-2.8 M
Current Value
-3.3 M
Quarterly Volatility
1.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
At this time, AIM ImmunoTech's Days Sales Outstanding is very stable compared to the past year. As of the 4th of March 2026, Days Of Sales Outstanding is likely to grow to 2,022, while Price To Sales Ratio is likely to drop 186.79. At this time, AIM ImmunoTech's Net Interest Income is very stable compared to the past year. As of the 4th of March 2026, Interest Income is likely to grow to about 6.3 M, while Operating Income is likely to drop (18.7 M). At this time, AIM ImmunoTech's Gross Profit is very stable compared to the past year. As of the 4th of March 2026, Gross Profit Margin is likely to grow to 0.99, while Pretax Profit Margin is likely to drop (123.02).
For AIM ImmunoTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AIM ImmunoTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AIM ImmunoTech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AIM ImmunoTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AIM ImmunoTech over time as well as its relative position and ranking within its peers.
Check out Trending Equities.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.By analyzing AIM ImmunoTech's earnings estimates, investors can diagnose different trends across AIM ImmunoTech's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for AIM ImmunoTech is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
AIM ImmunoTech is projected to generate -1.935575 in earnings per share on the 31st of December 2025. AIM ImmunoTech earnings estimates show analyst consensus about projected AIM ImmunoTech EPS (Earning Per Share). It derives the highest and the lowest estimates based on AIM ImmunoTech's historical volatility. Many public companies, such as AIM ImmunoTech, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing AIM ImmunoTech's earnings estimates, investors can diagnose different trends across AIM ImmunoTech's analyst sentiment over time as well as compare current estimates against different timeframes.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(18.16)
Revenue Per Share
0.106
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.95)
Return On Equity
(31.39)
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

AIM ImmunoTech Operating Margin vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining AIM ImmunoTech's current stock value. Our valuation model uses many indicators to compare AIM ImmunoTech value to that of its competitors to determine the firm's financial worth.
AIM ImmunoTech is rated below average in net income category among its peers. It is rated fifth in operating margin category among its peers . AIM ImmunoTech reported last year Net Loss of (15.59 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value AIM ImmunoTech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

AIM Operating Margin vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

AIM ImmunoTech

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(17.32 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

AIM ImmunoTech

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(94.12) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

AIM Operating Margin Comparison

AIM ImmunoTech is currently under evaluation in operating margin category among its peers.

AIM ImmunoTech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in AIM ImmunoTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, AIM ImmunoTech will eventually generate negative long term returns. The profitability progress is the general direction of AIM ImmunoTech's change in net profit over the period of time. It can combine multiple indicators of AIM ImmunoTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-17.8 M-18.7 M
Income Before Tax-15.6 M-16.4 M
Total Other Income Expense Net2.2 M1.7 M
Net Loss-15.6 M-16.4 M
Income Tax Expense1.9 M1.3 M
Net Interest Income5.3 M5.6 M
Interest IncomeM6.3 M
Net Loss-15.6 M-16.4 M
Net Loss-19.9 M-20.9 M
Net Loss(10.09)(10.60)
Income Quality 0.77  0.67 
Net Income Per E B T 1.12  1.08 

AIM Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on AIM ImmunoTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of AIM ImmunoTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the AIM ImmunoTech's important profitability drivers and their relationship over time.

AIM ImmunoTech Earnings per Share Projection vs Actual

Use AIM ImmunoTech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AIM ImmunoTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AIM ImmunoTech will appreciate offsetting losses from the drop in the long position's value.

AIM ImmunoTech Pair Trading

AIM ImmunoTech Pair Trading Analysis

The ability to find closely correlated positions to AIM ImmunoTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AIM ImmunoTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AIM ImmunoTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AIM ImmunoTech to buy it.
The correlation of AIM ImmunoTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AIM ImmunoTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AIM ImmunoTech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AIM ImmunoTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your AIM ImmunoTech position

In addition to having AIM ImmunoTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Marijuana Thematic Idea Now

Marijuana
Marijuana Theme
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
View All  Next Launch
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out Trending Equities.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
To fully project AIM ImmunoTech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of AIM ImmunoTech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include AIM ImmunoTech's income statement, its balance sheet, and the statement of cash flows.
Potential AIM ImmunoTech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although AIM ImmunoTech investors may work on each financial statement separately, they are all related. The changes in AIM ImmunoTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AIM ImmunoTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.